Safety and tolerability of CTH120, first-in-human phase I study encompassing three parts: Single and Multiple Ascending doses and potential Food Interaction

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502209-13-01

Acronym

CTH-CTH120-FIH-01

Enrollment

Registered

2023-05-17

Start date

2023-06-23

Completion date

2024-11-11

Last updated

2024-02-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fragile X syndrome

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026